Stimulants for depression: On the up and up?

Australian and New Zealand Journal of Psychiatry

Volumn 50, Issue 3, 2016, Pages 203-207

  Malhi, Gin S ^a,b   Byrow, Yulisha ^b   Bassett, Darryl ^c,d   Boyce, Philip ^e   Hopwood, Malcolm ^f   Lyndon, William ^e,g,h   Mulder, Roger ⁱ   Porter, Richard ⁱ   Singh, Ajeet ^j   Murray, Greg ^k  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF NOTRE DAME   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g Northside Clinic   (Australia)

^h ECT Services Northside Group Hospitals   (Australia)

ⁱ UNIVERSITY OF OTAGO   (New Zealand)

^j DEAKIN UNIVERSITY   (Australia)

^k SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

more..

Author keywords

amphetamine; depression; methylphenidate; modafinil; stimulants

Indexed keywords

ANTIDEPRESSANT AGENT; ARMODAFINIL; CITALOPRAM; DEXAMPHETAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE; MODAFINIL; PLACEBO; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; AMPHETAMINE; BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT;

BIPOLAR DEPRESSION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; HYPOMANIA; MANIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROBIOLOGY; OUTCOME ASSESSMENT; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BIPOLAR DISORDER; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR;

AMPHETAMINE; ANTIDEPRESSIVE AGENTS; BENZHYDRYL COMPOUNDS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DEXTROAMPHETAMINE; DRUG THERAPY, COMBINATION; HUMANS; METHYLPHENIDATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84975774442     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867416634208     Document Type: Review

References (25)

1. Abbasowa L, Kessing LV and Vinberg M (2013) Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials. Nordic Journal of Psychiatry 67: 369-382.
2. Calabrese JR, Frye MA, Yang R, et al. (2014) Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder. The Journal of Clinical Psychiatry 75: 1054-1061.
3. Calabrese JR, Ketter TA, Youakim JM, et al. (2010) Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: A randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. The Journal of Clinical Psychiatry 71: 1363-1370.
4. Carvalho AF, Berk M, Hyphantis TN, et al. (2014) The integrative management of treatmentresistant depression: A comprehensive review and perspectives. Psychotherapy and Psychosomatics 83: 70-88.
5. Connolly KR and Thase ME (2011) If At first you don't succeed: A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71: 43-64.
6. Corp S, Gitlin MJ, A and Altshuler LL (2014) A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. The Journal of Clinical Psychiatry 75: 1010-1018.
7. Dunlop BW, Crits-Christoph P, Evans DL, et al. (2007) Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: A double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 27: 614-619.
8. El-Mallakh RS (2000) An open study of methylphenidate in bipolar depression. Bipolar Disorders 2: 56-59.
9. Fava M, Thase ME and DeBattista C (2005) A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. The Journal of Clinical Psychiatry 66: 85-93.
10. Frye MA, Amchin J, Bauer M, et al. (2015) Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: Implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments. International Journal of Bipolar Disorders 3: 34.
11. Goss AJ, Kaser M, Costafreda SG, et al. (2013) Modafinil augmentation therapy in unipolar and bipolar depression. The Journal of Clinical Psychiatry 74: 1101-1107.
12. Ketter TA, Yang R and Frye MA (2015) Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. Journal of Affective Disorders 181: 87-91.
13. Lavretsky H, Reinlieb M, St Cyr N, et al. (2015) Citalopram, methylphenidate, or their combination in geriatric depression: A randomized, double-blind, placebo-controlled trial. The American Journal of Psychiatry 2015; 172: 561-569.
14. McElroy SL, Martens BE, Mori N, et al. (2015) Adjunctive lisdexamfetamine in bipolar depression: A preliminary randomized, placebo-controlled trial. International Clinical Psychopharmacology 30: 6-13.
15. Madhoo M, Keefe RS, Roth RM, et al. (2014) Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology 39: 1388-1398.
16. Malhi GS and Byrow Y (2016) Is treatment-resistant depression a useful concept? Evidence Based Mental Health 19: 1-4.
17. Malhi GS, Bassett D, Boyce P, et al. (2015a) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian and New Zealand Journal of Psychiatry 49: 1087-1206.
18. Malhi GS, Lingford-Hughes AR and Young AH (2016) Antidepressant treatment response: 'I want it all, and I want it now!' The British Journal of Psychiatry 208: 101-103.
19. Malhi GS, Masson M and Bellivier F (2015b) Teasing apart Bipolar III: The causes and consequences of a Treatment-Emergent Affective Switch (TEAS) into mania. Australian and New Zealand Journal of Psychiatry 49: 866-868.
20. Nelson JC (2015) The Role of Stimulants in Late-Life Depression. The American Journal of Psychiatry 172: 505-507.
21. Orr K and Taylor D (2007) Psychostimulants in the treatment of depression: A review of the evidence. CNS Drugs 21: 239-257.
22. Ostacher MJ (2014) When positive isn't positive: The hopes and disappointments of clinical trials. The Journal of Clinical Psychiatry 75: e1186-e1187.
23. Patkar AA, Masand PS, Pae CU, et al. (2006) A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. The Journal of Clinical Psychopharmacology 26: 653-656.
24. Ravindran AV, Kennedy SH, O'Donovan MC, et al. (2008) Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: Results of a double-blind, randomized, placebo-controlled trial. The Journal of Clinical Psychiatry 69: 87-94.
25. Trivedi MH, Cutler AJ, Richards C, et al. (2013) A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. The Journal of Clinical Psychiatry 74: 802-809.